Business Context and Reporting Period
This Form 8-K Current Report was filed by aTyr Pharma, Inc. on June 30, 2017. The filing discloses the entry into a material definitive agreement involving a loan amendment and the issuance of unregistered equity securities.
Key Financial Metrics and Agreements
- Loan Facility: The Company entered into the First Amendment to its Loan and Security Agreement with Silicon Valley Bank and Solar Capital Ltd., providing for up to $20.0 million in term loans across three tranches.
- Funding Received: The second tranche of $5.0 million was funded on June 30, 2017.
- Warrant Issuance: In connection with the loan, the Company issued warrants to each lender to purchase 20,833 shares of common stock.
- Warrant Terms: The exercise price is $3.60 per share. Warrants are immediately exercisable and expire on June 30, 2024.
Material Changes and Conditions
The Loan Amendment modifies the conditions for drawing down term loans:
- Second Tranche: Up to $5.0 million may be drawn at the Company's discretion prior to June 30, 2017, without milestone requirements.
- Third Tranche: An additional $5.0 million may be drawn after June 30, 2017, subject to achieving certain milestones.
- Security Requirements: If milestones are not met by August 31, 2017, the Company must secure the second tranche with cash. If milestones are not met by October 31, 2017, the Company must either maintain cash security or pre-pay the second tranche.
Outlook, Risks, and Contingencies
The filing highlights specific contingencies tied to operational milestones. Failure to meet these milestones by the specified dates (August 31 and October 31, 2017) triggers liquidity constraints, requiring the Company to either lock up cash as collateral or repay the loan early. The filing does not provide specific revenue, profit, or cash flow figures for the period, as this is a current report focused on a specific transaction rather than a periodic financial statement.
Investor Verification Checklist
- Verify the specific operational milestones required to avoid cash collateralization or prepayment of the $5.0 million second tranche.
- Confirm the total outstanding debt balance following the June 30, 2017 funding.
- Review the dilution impact of the 41,666 total warrant shares issued to lenders.
- Check the Company's cash position to assess its ability to secure the loan if milestones are missed.